<DOC>
	<DOC>NCT00982930</DOC>
	<brief_summary>This is an open-label, single arm (uncontrolled) study in subjects suffering from cystic fibrosis, who have completed their study participation in CTBM100C2303 (all visits) and who were proven infected with Pseudomonas aeruginosa at enrollment into CTBM100C2303.</brief_summary>
	<brief_title>Open Label Extension to Bridging Study CTBM100C2303</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Completed all visits in study CTBM100C2303, and visit 4 took place not more than 5 days before enrollment into this study. Confirmed diagnosis of cystic fibrosis patients with P. aeruginosa infection. FEV1 at screening (study CTBM100C2303) must be between 25% and 80% of normal predicted values. Any use of inhaled antipseudomonal antibiotics between the termination of the core trial CTMB100C2303 and the enrollment into this study. Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Tobramycin Inhalation Powder</keyword>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Lung diseases</keyword>
	<keyword>Anti-Bacterial Agents</keyword>
</DOC>